News Hub | News Direct

One In Five Americans Could Develop Skin Cancer In Their Lifetime – AiViva’s Novel Drug Approach Could Help

AiViva BioPharma

Interested in investing in AiViva’s campaign? Click here to get started! Cancer is one of the most dreaded diseases in the modern world. In the United States. S kin cancer is the most common form of cancer with current estimates indicating that one in five Americans could potentially develop skin cancer in their lifetime. Research estimates that non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), affects more than 3 million Americans a year. Basal cell carcinoma (BCC), a non-melanoma skin cancer, is the most common form of skin cancer and also the most frequently occurring of all cancers. BCC is said to occur when changes are triggered in the basal cells in the outermost layer of the skin (called the epidermis) due to DNA damage resulting from exposure to ultraviolet (UV) radiation from the sun, or from indoor tanning. These changes result in the abnormal and uncontrolled growth of basal cells giving rise to BCC. When detected early, most basal cell carcinomas (BCCs) can be treated and cured but prompt treatment is vital, and certain rare, aggressive forms can be fatal if not treated promptly. A Promising Potential Treatment For Basal Cell Carcinoma? One company that is testing a novel approach to treating BCC and believes it could potentially produce transformative outcomes is AiViva Biopharma. AiViva says that its treatment is unique because it avoids surgery entirely, and comprises injecting the AiViva compound AIV001 directly into the cancer area. Its proprietary technology enables a prolonged release of AIV001 directly to the targeted cancer without systemic side effects or visible scarring. AiViva’s clinical trial is ongoing, targeting two of the four main clinical subtypes of basal cell carcinoma: nodular and superficial in patients. The company says that the preliminary data available from this study is promising, and notes that AIV001 is able to demonstrate its ability for histological clearance of BCC skin cancer. This preliminary result affirms AiViva’s belief that AIV001 could potentially treat and cure superficial and nodular basal cell carcinomas. “We believe that AIV001 has the potential to transform the treatment paradigm for BCC by offering a disease-modifying therapy providing physicians and patients with an effective treatment. We look forward to sharing data from our trial at its conclusion.” said Dr. Diane Tang-Liu, President and CEO of AiViva. The company expects the topline results from the AIV001 trial for BCC to be available in 2023. About AiViva Biopharma: AiViva is a clinical stage biotech company founded in 2015 by four pharmaceutical industry veterans with more than 300 years of combined industry experience. AiViva's founders have demonstrated a successful track record across the full spectrum of drug development and commercialization, in addition to raising capital, and IPOs on the NYSE and NASDAQ.AiViva was formed with the mission of developing novel, innovative pharmaceutical products through an efficient, risk-mitigated development strategy to address major unmet medical needs.We are developing drug products with the potential to transform treatment paradigms or significantly reduce the treatment burden for patients and physicians. Our approach leverages our proprietary JEL™ Technology to prolong the therapeutic effects of drugs and enhance their benefit-risk profiles. AiViva has a diverse pipeline of multiple novel drug candidates in development areas of dermatology, ophthalmology, oncology, and urology with the potential to expand to other areas of interest. Click here to invest in AiViva and be a part of their growth story. If you would like to learn more about the company, check out its website. AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ. The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. Contact Details Michael office@aiviva.com Company Website https://aiviva.com/

December 13, 2022 03:45 PM Eastern Standard Time

CoorsTek Achieved Another Legal Victory Against CeramTec in Fight to Market “Pink” Ceramic Hip Components

CoorsTek

CoorsTek Bioceramics announced today that the US PTO Trademark Trial and Appeal Board (TTAB) has ruled in its favor cancelling CeramTec GmbH’s trademarks in the color pink. The ruling again affirms CoorsTek Bioceramics’ right to market and sell its pink CeraSurf®-p ceramic hip replacement components in the US. The proceeding was initiated by CoorsTek Bioceramics (formerly C5 MedicalWerks) in 2014 in response to an attempt by CeramTec to enforce its claimed trademark and trade dress in the color pink for its ceramic hip implant components. In its order, the TTAB found the color pink covered by the CeramTec trademark registrations to be functional, and therefore unregistrable. CoorsTek Bioceramics CeraSurf®-p material is a state-of-the-art technical ceramic material containing a chromium oxide additive for improved performance including increased hardness. The pink coloring of products manufactured from CeraSurf®-p ceramic is a natural byproduct of the additive. “Recent global events have cast a bright light on the dangers of singular or limited supply sources in key markets,” said Jonathan Coors, CEO of CoorsTek. “This decision will not only ensure a consistent supply of crucial components, it will foster competition, drive innovation, and enable efficiencies in the surgical marketplace—ultimately benefitting patients receiving critical medical care.” Clinical evidence shows femoral heads (hip balls) manufactured from CeraSurf®-p ceramic material demonstrate exceptional mechanical performance and durability. Hip systems incorporating CeraSurf®-p hip components were initially cleared for regulatory use in Brazil in 2011and have since been registered for use by customers of CoorsTek Bioceramics in the US, China, the EU, and Japan. Additional worldwide regulatory clearances are pending. “CoorsTek Bioceramics offers increased confidence to medical device OEMs and the surgeons reliant on these products,” said Lucian Strong, Vice President of CoorsTek Bioceramics. “With the growing popularity of ceramic bearing surfaces used in hip arthroplasty, it is essential for healthcare providers to have access to high-quality, substantially equivalent options.” The ruling comes at a good time for CoorsTek Bioceramics, as the company recently broke ground on a major expansion of its manufacturing facility in Grand Junction, CO USA. The expansion will vastly increase the company’s capacity for manufacturing the advanced ceramic hip components. CeramTec GmbH has until early February 2023 to file an appeal of the TTAB trademark cancellation order. Similarly in the EU in 2021, the Paris Court of Appeals upheld the cancellations of the three EU trademarks and the dismissal of CeramTec’s trademark infringement and parasitic competition claims against CoorsTek. The Court confirmed the trademarks were filed in bad faith and additionally ordered CeramTec to pay damages for abuse of trademark law, thus clearing the pathway for CoorsTek to market CeraSurf®-p products in the European Union. Read more on the 2021 decision. About CoorsTek Bioceramics CoorsTek Bioceramics is dedicated to leading edge manufacturing of technical ceramic implant components for the medical device industry. A wholly owned subsidiary of CoorsTek, Inc., CoorsTek Bioceramics is backed by over 100 years of technical ceramics expertise. With a focus on ceramic bearing surfaces for total joint arthroplasty, CoorsTek Bioceramics components can also be found in implant devices for neurological, cardiological, spinal, and radiation applications. Since 2005, over six million CoorsTek Bioceramics components have been sold and distributed for clinical use. About CoorsTek Founded in 1910 and continuously owned and operated by the Coors family, CoorsTek is a leading global manufacturer of technical ceramics. By leveraging expertise in engineering and materials science, CoorsTek provides solutions to complex challenges in the medical, semiconductor, automotive, aerospace, and other industries. With over 400 proprietary material formulations, vertically integrated systems, and unparalleled process capabilities, CoorsTek partners with its customers to make the world measurably better. Visit www.coorstek.com Contact Details CoorsTek Megan Maguire +1 303-503-2287 mmaguire@coorstek.com Company Website https://www.coorstek.com

December 13, 2022 11:39 AM Eastern Standard Time

Futura Medical "on track" for launch in H1 2023

Futura Medical PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 13, 2022 08:08 AM Eastern Standard Time

Video

Wellness Access Institute launches to accelerate the speed of innovation from the science to shopper

Wellness Access Institute

The fast-growing global health & wellness industry is now worth US$1.5 trillion and is projected to grow at a rate of 5-10% per year ( Mckinsey & Company ). While every company rushes to bring new products to market to take a slice of the revenue opportunity, consumers are faced with a different dilemma. What innovations or brands can they trust? Which products are genuinely backed by science-based evidence and real-world proof? What actions can they take now to support their long term health and wellness? And how can they get a hold of the latest cutting edge research and solutions sooner? Wellness Access Institute (WAI) aims to position itself as the leading authority and innovation accelerator in the Wellness industry. Established in June 2022 by Greg Macpherson and Warren Liu, WAI (Pronounced ‘why’) aims to address the industry's biggest problems. Whether it's predicting the future of the industry, educating consumers on the science, addressing the trust deficit or tackling issues with supply chain quality and speed to market for products. WAI’s goal is to establish an independent industry body that is funded by the industry it hopes to serve. Warren Liu, Co-Founder of WAI says “WAI aims to enforce, advance and advocate the wellness movement to benefit the health of the human race. The idea came to me and my co-founder Greg given our work together on launching the SRW Cellular Health brand. We realised a number of issues in bringing genuine innovation to market with a lack of platforms, information and support for those that haven’t been through the process before. It's from this realisation that we had the idea to create a solution”. Ahead of the launch today, Warren and Greg have been able to establish an initial advisory board featuring some of the best minds from across the industry. “With our advisory board we hope to answer the what, why and how of the industry in a way that helps accelerate the wellness movement globally” says Greg Macpherson, Co-Founder of WAI. “Along with solving some of the key industry issues; this advisory board will work on their collective 2030 vision for wellness and support with the latest scientific research”. The wellness advisory board features 8 prominent individuals: From Aubrey Levitt the founder of microbiome startup ‘Postbiotics Plus’, to Dr. Matt Yousefzadeh who has published over 30 scientific publications to Michael Heinam who has secured patent applications and contracts with leading universities and researchers, in over 145 countries around the world. The initial team brings with them a network of thousands of potential collaborators across the globe. Warren Liu added: “Ultimately this diverse panel is what makes WAI different. It's no longer just businessmen and scientists trying to create new products to sell. It's an open dialogue and vision setting agenda involving people at every stage of the journey and starts with making knowledge on the primary factors for wellness accessible to all. From a discussion on what you can do today to be healthier, right down to the young person suffering acne problems who may end up buying a product from TikTok” The WAI accelerator program will also be a critical ignition tool for change. The industry is known for its red tape and often our best scientists take years to bring the latest innovations to people who need them, let alone in a way that is accessible and affordable. For the first time WAI will be able to connect scientists with the best minds in R&D, Entrepreneurship, Technical Production, Supply Chain, Marketing, Culture, Education, Government and Industry. Greg Macepherson said: “WAI is here to surface foundational aspects of how we all age healthier and make this knowledge accessible to all. We are here to foster conversation and change to move humanity’s health and wellness forward. There is something fundamentally broken at a population level around health and wellness and an urgent paradigm shift is needed if we are to support an ageing population sustainably and improve our collective and individual health as we age. WAI aims to accelerate our understanding and access to wellness and wellness innovation in a way that is trusted and available to all. Improving “Access’ to the latest innovations is core to our mission.” Warren and Greg have been discussing specific problems in the industry that they believe they can begin to solve right away. With Greg’s background as a biotechnologist, futurist, Founder of SRW Laboratories and author of ‘The 9 Hallmarks of Ageing’ he has identified an issue that is very personal to both of them. “How we classify, understand and provide cutting edge solutions to ageing will be one of the group’s first missions. How we think about our cellular health and supporting a dialogue to classify ageing as a disease is a fundamental issue to raise awareness of. A similar parallel is when scientists reached consensus that microbes caused infections. This consensus caused a change in behaviours such as adopting basic hygiene principles saving hundreds of thousands of lives and then led to the discovery of antibiotics that saved millions more. Once we think of ageing as a disease then it will drive changes to behaviours that cause us to slow the ageing process and ultimately will lead to the discovery of “antibiotics” for ageing that will lead to increased health-spans and lifespans for us all - the benefits of this for humanity are significant” added Greg Macepherson. Beyond addressing core facets of how we improve accessibility to knowledge around health and wellness that will drive a step change in how well people age, an issue right now is that there are some amazing breakthroughs happening in the research space. We need to set up frameworks to massively accelerate research and access to these breakthroughs. The reality is that most everyday citizens don’t know that there is clear science on how to slow aging. Or how to even begin to translate this and take action for themselves. By focusing on raising awareness of the issue itself, WAI hopes to educate the end customer on what solutions are available. And collaborating directly with scientists, labs and researchers to help bring affordable solutions to customers right now. WAI also aims to raise awareness about the benefits of gut health and nutrition as ways to ward off disease. Most consumers aren’t aware of the latest research in phytonutrients and how they can act as the ingredients for your body's own compound pharmacy - your gut microbiome. One that can produce its own medicines, now known as postbiotics, that support our overall health. When we think about nutrition we have actually been sold a lie for many years. We can all remember the phrase ‘eat your greens’. This was actually born out of an opportunity to sell green supplements to those who didn’t eat green fruits and vegetables because they didn’t like the taste. Fast forward to today and the market is flooded with hundreds of greens based supplements and multivitamins. We seem to have forgotten about the other 5 major colours based on this clever marketing ploy. We actually need to be eating red, purple, blue, yellow, green and black fruits and vegetables of every colour. And these need to contain genuine phytonutrients in order for our bodies to be able to create their own solutions. 90% of the health and wellness market doesn’t even consider this. Finally they have also set our sights on the beauty industry and its endless and often toxic pursuit of beauty. We aim to raise awareness of the skin biome and how that affects how we think about beauty from the inside out. Warren has previously worked with ‘Vida Glow’ who pioneered the ingestible beauty industry so he knows this space well. “We aren’t just talking about marine collagen here however; we are looking to tackle the serious issue of beauty culture through education and innovation” commented Warren Liu. Full list of WAI Advisory Board members: Aubry Levitt, Dr Andrew Clark, Dr Matt Yousefzadeh, Michael Henain, Aki Ueda, Dr Ross Walker and Dr Albert Dashi. About Wellness Access Institute Wellness Access Institute (WAI, pronounced ‘why’) is a non-for-profit organisation that aims to position itself as the leading authority and innovation accelerator in the wellness industry. Established in June 2022 by Greg Macpherson and Warren Liu, WAI aims to solve some of the industry's biggest problems. Whether it's predicting the future of the industry, educating consumers on the science, addressing the trust deficit created by untrustworthy sellers (citizen scientists) or tackling issues with supply chain quality and speed to market for products. For more information please visit https://wai.institute/ or follow via Linkedin or instagram. Contact Details Wellness Access Institute Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://wai.institute/

December 13, 2022 06:00 AM Eastern Standard Time

Image

SpectrumX Holdings ready for first in-human clinical trial

SpectrumX Holdings UK Ltd

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 13, 2022 04:33 AM Eastern Standard Time

Video

WINTERIZING YOUR BEAUTY & SKINCARE REGIME

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/sTgZk9M1aiA MORE MOISTURE: It’s the time of year many people may be experiencing itchy and dry skin. That’s because as the temperature drops and ambient humidity lowers, our skin tends to lose its protective, physical barrier function. The beauty and lifestyle expert says now is the time to boost hydration, since it’s essential to supporting a natural, healthy glow. “A great way to do this is with skincare products containing rosewater. This is something I swear by,” adds Foley. Rosewater for skin helps to balance natural oils, reduce the appearance of temporary redness and hydrate skin naturally. Two affordable products from NOW® Solutions are this Soothing Rose Facial Cleansing Oil and Rosewater Rejuvenating Mist. Foley says, “Switching to an oil-based cleanser in the winter months is key to preserving our natural protective barrier and moisture. It’s a gentle way to remove make-up, SPF, and pollutants while nourishing our skin.” She points out how the mist is a multipurpose freshening solution that instantly hydrates and revitalizes dry or sensitive skin. “You can use it to set makeup, after the gym or just to refresh skin any time of day,” says Foley. Both products are Certified Cruelty Free, paraben free, gluten free, quality tested for purity, and vegan. Find out more at nowfoods.com. Direct link: www.nowfoods.com Social media handles: Facebook: @nowfoodsofficial Instagram: @nowfoodsofficial Twitter: @nowfoods FEEL & LOOK YOUR BEST: Foley says a proper skincare routine can really help with the signs of aging, adding, “I’m a big fan of the StriVectin - Tighten & Lift Set.” This set is complete with Contour Restore Tightening & Sculpting Face Cream and the TL Advanced Tightening Neck Cream PLUS. The face cream visibly restores contour and youthful-looking bounce to your face and jawline with a clinically proven firming moisturizer. It’s formulated with Elastin-Targeting Dipeptides to address loss of volume and sagging skin for a visibly lifted, plump look. The TL Advanced Tightening Neck Cream PLUS smooths the appearance of lines and wrinkles on the neck. This is the #1 selling cream exclusively for the Neck & Décolleté. It features the breakthrough Gravitite-CF Lifting Complex™ to improve skin elasticity and provide visible lift, while smoothing the appearance of horizontal neck lines and sagging. For more information, go to Strivectin.com. Social media handles: Instagram: @strivectin Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 12, 2022 11:44 AM Eastern Standard Time

Video

A.I. in New Drug Discovery and Development Takes Center Stage at New York Health Forum (226330.KQ)

Syntekabio, Inc.

The 19 th New York Health Forum, hosted by W Medical Strategy Group, celebrated its year end on Nov. 28 with a successful gathering of physicians, executives and policymakers from biomedical, pharmatech and government organizations at the Press Lounge in Hudson Yards, Manhattan’s newest business and cultural hub. Led by Syntekabio CEO Jongsun Jung, executives of Syntekabio USA (226330:KQ)(226330:KS) joined the exclusive dinner event to meet and network with health industry leaders and innovators from the U.S. and Korea. They shared presentations and conversations on healthcare market trends and technologies while soaking in a breathtaking view of New York’s famed skyscrapers and city lights. The New York Health Forum is well known for bringing together global health industry stakeholders to connect and illuminate timely topics that impact the development and businesses of biomedicine and life sciences. During the pandemic, the forum hosted a year-long series of webinars online. Sanghee Kim, minister counselor at the Embassy of the Republic of Korea, and DoHyun Cho, Ph.D., chairman of the New York Health Forum, warmly welcomed the guests. A robust information seminar soon followed on breaking into the U.S. healthcare market through collaborative global partnerships. Featured presentations included KHIDI’s roles in assisting Korean companies’ entry into the U.S. healthcare industry by Soonmahn Park, Ph.D., president of KHIDI USA, and the state of A.I. in new drug discovery and development by Kilyoung Kim, Ph.D., president of Syntekabio USA. According to Kim, Syntekabio’s groundbreaking AI platform DeepMatcher® efficiently performs tasks critical for discovering new synthetic drug candidates on a massive scale. DeepMatcher® is able to screen more than 1 billion compounds per target protein. The power of biotech innovation is captured in the way it virtually combines three-dimensional binding structures to predict and quickly derive accurately small molecule drug candidates. A biopharmaceutical game changer, Syntekabio’s latest cloud platform system will launch in the U.S. before the end of the year 2022. During the dinner, Dr. Sanghyun Alex Kim, MD, president of KAMPANY, introduced the vision of Korean American physicians and his work as associate professor of Surgery at the Icahn School of Medicine at Mount Sinai. Several physicians also shared their views on how today’s rapidly evolving technologies are impacting their mission in treating patients, including leveraging A.I.-based cloud systems such as Syntekabio’s suite of cloud platforms. Attendees also learned about the global healthcare industry trends and the latest technologies disrupting the marketplace. Peter Lee, director of InnoTherapyAmerica Inc. spoke about InnoTherapy technology’s advantages. Seung Woo Song, vice president of Psomagen, updated the audience on the genomics/proteomics clinical research services they provide. Moderated by James Bae, senior advisor of New York Health Forum, the program highlighted opportunities and challenges for the U.S.-Korea pharma industry both in short- and long-term perspectives. The event continued well into the evening with guests, including U.S. representative Han S. Bang of ST Pharm, a Dong-A company; Dr. Isabella Park, the Korean medical program head for Northwell Health; and Dr. Yoojin Kim, an internist for Montefiore, to name a few. To learn more about Syntekabio USA, visit https://www.syntekabio.com/eng. ### SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng

December 12, 2022 09:22 AM Eastern Standard Time

Image

Poolbeg Pharma receives initial results from human challenge clinical study

Poolbeg Pharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 12, 2022 06:59 AM Eastern Standard Time

Video

Evgen Pharma "cash runway in pretty good shape"

Evgen Pharma PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 12, 2022 06:53 AM Eastern Standard Time

Video

Healthcare

One In Five Americans Could Develop Skin Cancer In Their Lifetime – AiViva’s Novel Drug Approach Could Help

CoorsTek Achieved Another Legal Victory Against CeramTec in Fight to Market “Pink” Ceramic Hip Components

Futura Medical "on track" for launch in H1 2023

Wellness Access Institute launches to accelerate the speed of innovation from the science to shopper

SpectrumX Holdings ready for first in-human clinical trial

WINTERIZING YOUR BEAUTY & SKINCARE REGIME

A.I. in New Drug Discovery and Development Takes Center Stage at New York Health Forum (226330.KQ)

Poolbeg Pharma receives initial results from human challenge clinical study

Evgen Pharma "cash runway in pretty good shape"